Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.
Biosimilar to Remicade
Expected U.S. launch in 2023.
Biosimilars may need more time to devleop in the market.
Biologic medicines could lower spending by $153 billion by 2023.
New changes are making it more difficult for generics and biosimilars to compete on formularies.
Blockbuster drug could be key to Humira’s successor.
CD20-directed antibody indicated for several cancers and other conditions.
Biosimilar guidance provides “clarity” for drug developers.
Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma.